Correction: Angiosarcoma patients treated with immune checkpoint inhibitors: A case series of seven patients from a single institution (Journal for ImmunoTherapy of Cancer DOI: 10.1186/s40425-019-0689-7)

Vaia Florou, Andrew E. Rosenberg, Eric Wieder, Krishna V. Komanduri, Despina Kolonias, Mohamed Uduman, John C. Castle, Jennifer S. Buell, Jonathan Trent, Breelyn A. Wilky

Research output: Contribution to journalComment/debate

Abstract

Following publication of the original article [1], the authors have reported that the following sentence "While of the same IgG1 class as ipilimumab, preclinical data suggests this molecule may have enhanced activity against T regulatory cells".

Original languageEnglish (US)
Article number285
JournalJournal for ImmunoTherapy of Cancer
Volume7
Issue number1
DOIs
StatePublished - Nov 6 2019

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Molecular Medicine
  • Oncology
  • Pharmacology
  • Cancer Research

Fingerprint Dive into the research topics of 'Correction: Angiosarcoma patients treated with immune checkpoint inhibitors: A case series of seven patients from a single institution (Journal for ImmunoTherapy of Cancer DOI: 10.1186/s40425-019-0689-7)'. Together they form a unique fingerprint.

  • Cite this